medigraphic.com
ISSN 0210-5187 (Electronic)

2007, Number 5

<< Back Next >>

Med Cutan Iber Lat Am 2007; 35 (5)

Cutaneous melanoma and pregnancy

Antonio Tejera Vaquerizo, Almudena Fernández Orland, Elena Gallego, Rosa Castillo Muñoz, Matilde Mendiola Fernández, Enrique Herrera Ceballos

Language: Spanish
References: 21
Page: 225-228
PDF size: 150.37 Kb.


ABSTRACT

The aim of this essay consists of comparing several clinicalpathologic features between pregnancy-related melanoma and pregnancy-non related melanoma.
We included 107 women with melanoma (15 cases and 92 controls). They were grouped into two intervals, 1988-1996 and 1997-2004. The essaytook into account variables such as: age, location, histologic type, thickness and time of diagnostic delays. An immunohistochemical analysis of estrogen and progesterone receptor, c-erb-B2 and Ki-67 was made in 10 melanomas (5 cases and 5 controls).
The results displayed a similar age, location and anatomoclinical type in both groups. As far as the interval analysis is concerned, the thickness tumourwas higher in the cases in the 1988-1996 interval (1.87 mm vs1.46 mm; p = 0.49). Besides, the time of diagnostic delays was longer (35.11 months vs20.4 months; p = 0.05). These differences were no evidents in the 1997-2004 period (1.34 mm vs1.41 mm; p = 0.92; 16 months vs18.1 months; p =0.69 ). No immunoexpression of hormonal receptors and c-erb-B2 was evident. Similarly, Ki-67 was presented in both groups.
In conclusion, real differences between pregnancy-related melanoma and pregnancy non-related cannot be observed, including thickness and time ofdiagnostic delays.


REFERENCES

  1. Stang A, Stabenow R, Eisinger B, et al. Site and gender-specific time trend analyses of incidence of skin melanomas in the formerGerman Democratic Republic (GDR) including 19351 cases. Eur J Cancer2003;39:1610-1618.

  2. MacKie RM, Bray C, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lan-cet 2002;360:587-591.

  3. Nieto A, Ruiz-Ramos M, Abdel-Kader K, et al. Gender differences in rising trends in cutaneous malignant melanoma in Spain,1975-98. Br J Dermatol 2003;148:110-116.

  4. Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influence and risk of melanoma in women. Int J Epidemiol 1998;27:751-757.

  5. Wong DJ, Stassner HT. Melanoma in pregnancy. Clin Obstet Gynecol 1990;33:282-291.

  6. Richard KA, Stasko T. Dermatologic surgery and the pregnant patient. Dermatol Surg 2002;28:248-256.

  7. Travers RL, Sober AJ, Berwick M, et al. Increased thickness of pregnancy-associated melanoma. Br J Dermatol 1995;132:876-883.

  8. Daryanani D, Plukker FTh, De Hullu JA, et al. Pregnancy and early-stage melanoma. Cancer 2003;97:2248-2253.

  9. Duffi MJ. Predictive markers in breast and other cancer: a review. Clin Chem 2005;51:494-503.

  10. Pack GT, Scharnagel IM. The prognosis for malignant melanoma in the pregnant women. Cancer 1951;4:324.

  11. Winton GB, Lewis CW. Dermatoses of pregnancy. J Am Acad Dermatol 1980;6:977-998.

  12. O’Meara AT, Cress R, Xing G, et al. Malign antmelanoma in pregnancy. Cancer 2005;103:1217-1226.

  13. Nieto A, Ruiz-Ramos M, Abdel-Kader L, et al. Gender differences in rising trends in cutaneous malignant melanoma in Spain,1975-98. Br J Dermatol 2003;148:110-116.

  14. Richard MA, Grob JJ, Avril MF, et al. Melanoma and tumor thickness. Arch Dermatol 1999;135:269-274.

  15. Schmid-Wendtner MH, Baumert J, Stange J and Volkenandt M. Delay in the diagnosis of cutaneous melanoma: an analysis of 233patients. Melanoma Research 2002;12:389-394.

  16. Baccard M, Chevret S, Chemaly Ph and Morel P. Délai de diagnostic du mélanome.Ann Dermatol Venereol 1997;124:601-606.

  17. Richard MA, Grob JJ, Avril MF, et al. Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer(Pred Oncol) 2000;89:271-279.

  18. Richard MA, Grob JJ, Avril MF, et al. Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer (Pred Oncol) 2000;89:280-285.

  19. Duncan LM, RL Travers, Koerner FC, et al. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: absen-ce o immunohistochemically detectable hormone receptors. Hum Pathol1994;25:36-41.

  20. Fink-Puches R, Pilarski P, Schmidbauer U, et al. No evidence for c-erb-B2 overexpression in cutaneous melanoma. Anticancer Res 2001;21:2793-2795.

  21. Böni R, Doguoglu A, Burg G, et al. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35:416-418.




2020     |     www.medigraphic.com